Toxic microbiome and progression of chronic kidney disease: insights from a longitudinal CKD-Microbiome Study
Manolo Laiola, Laetitia Koppe, Islam Amine Larabi, Florence Thirion, Céline Lange, Benoît Quinquis, Aymeric David, Emmanuelle Le Chatelier, Bérengère Benoit, Giuseppina Sequino, Stéphanie Chanon, Aurélie Vieille‐Marchiset, Yves-Édouard Herpe, Jean‐Claude Alvarez, G. Glorieux, Hubert Krukowski, Geert Huys, Jeroen Raes, Denis Fouque, Ziad Massy, S. Dusko Ehrlich, Bénédicte Stengel, Sandra Wagner
Abstract
BACKGROUND: The gut microbiota has been linked to non-communicable diseases, including chronic kidney disease (CKD). However, the relationships between gut microbiome composition changes, uraemic toxins (UTs) accumulation, and diet on CKD severity and progression remain underexplored. OBJECTIVE: To characterise relationships between gut microbiome composition and functionality, UTs diet, and CKD severity and progression, as well as assess microbial contributions to UTs accumulation through mice faecal microbiota transplantation (FMT). DESIGN: cohort. A multiomics approach identifies features associated with CKD severity (and progression), with validation in an independent Belgian cohort. Experimental models used FMT to test CKD gut microbiome effects on UTs and kidney fibrosis. Changes in gut microbiome over time were evaluated, and the impact of diet on these changes was assessed. RESULTS: Compared with matched healthy controls, patients with CKD exhibited gut microbiota alteration, with enrichment of UT precursor-producing species. Patients with severe CKD exhibited higher UT levels and greater enrichment of UT (precursor)-producing species in the microbiota than patients with moderate CKD. Over time, UT (precursor)-producing species increased, and a plant-based low protein diet appeared to mitigate these changes. FMT from patients with CKD to antibiotic-treated CKD model mice increased serum UT levels and exacerbated kidney fibrosis. CONCLUSIONS: This study highlights the role of the microbiome and UTs in CKD, suggesting a potential therapeutic target to slow disease progression.